Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

Fig. 1

Distinct reduction of CP13-positive tau profiles by late-stage Anle138b treatment in hTau mice. Representative immunohistochemistry images of the frontal cortex (a, b) and the hippocampus (c, d) are shown for hTau mice after 3 months treatment with Anle138b or vehicle. Quantification indicated significant reductions of tau load and CP13-positive neurons in the frontal cortex (e, g) and the hippocampus (f, h). Error bars represent SEM

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193